JP2020511468A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511468A5
JP2020511468A5 JP2019550653A JP2019550653A JP2020511468A5 JP 2020511468 A5 JP2020511468 A5 JP 2020511468A5 JP 2019550653 A JP2019550653 A JP 2019550653A JP 2019550653 A JP2019550653 A JP 2019550653A JP 2020511468 A5 JP2020511468 A5 JP 2020511468A5
Authority
JP
Japan
Prior art keywords
disease
fibrosis
syndrome
disorder
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019550653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511468A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/022545 external-priority patent/WO2018170201A1/en
Publication of JP2020511468A publication Critical patent/JP2020511468A/ja
Publication of JP2020511468A5 publication Critical patent/JP2020511468A5/ja
Pending legal-status Critical Current

Links

JP2019550653A 2017-03-16 2018-03-15 Mk2阻害剤の重水素化アナログおよびその使用 Pending JP2020511468A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472022P 2017-03-16 2017-03-16
US62/472,022 2017-03-16
PCT/US2018/022545 WO2018170201A1 (en) 2017-03-16 2018-03-15 Deuterated analogs of mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2020511468A JP2020511468A (ja) 2020-04-16
JP2020511468A5 true JP2020511468A5 (enExample) 2021-04-22

Family

ID=63523341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550653A Pending JP2020511468A (ja) 2017-03-16 2018-03-15 Mk2阻害剤の重水素化アナログおよびその使用

Country Status (4)

Country Link
US (1) US11230551B2 (enExample)
EP (1) EP3596085A4 (enExample)
JP (1) JP2020511468A (enExample)
WO (1) WO2018170201A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
WO2018170200A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
CN116670142A (zh) 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
CN115925718A (zh) * 2022-12-27 2023-04-07 瑞石生物医药有限公司 一种四环内酰胺衍生物及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
MX2009014247A (es) 2007-07-16 2010-01-28 Novartis Ag Compuestos heterociclicos utiles como inhibidores de mk2.
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2014011902A1 (en) * 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
US9457707B2 (en) * 2014-09-15 2016-10-04 Nissan North America, Inc. Vehicle auxiliary lamp unit
RS62017B1 (sr) * 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2020511468A5 (enExample)
JP2020512315A5 (enExample)
JP2020514361A5 (enExample)
JP2020514360A5 (enExample)
CN109071448B (zh) Ask1抑制剂及其制备方法和应用
WO2022171184A1 (zh) 作为sos1抑制剂的杂环化合物
CN103492370B (zh) 取代的二氨基甲酰胺和二氨基甲腈嘧啶,其组合物,和用其治疗的方法
JP5916752B2 (ja) 5−クロロ−n2−(2−イソプロポキシ−5−メチル−4−ピペリジン−4−イル−フェニル)−n4[2−(プロパン−2−スルホニル)−フェニル]−ピリミジン−2,4−ジアミンの結晶形
JP2024113019A5 (enExample)
JP2011513485A5 (enExample)
JP2020523390A5 (enExample)
JP2013545812A5 (enExample)
JP2022542434A5 (enExample)
CA3019450A1 (en) Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application
JP2019524660A5 (enExample)
JP2022531088A5 (enExample)
JP6830888B2 (ja) Jak阻害剤の硫酸水素塩の結晶形およびその製造方法
PT1735286E (pt) Moduladores de canabinóides à base de tetrahidro-indazol
JP2007509043A5 (enExample)
ES2817448T3 (es) Compuestos de pirimidina como inhibidores de quinasas
JP2022521413A5 (enExample)
JP2019507776A (ja) ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用
ES2340201T3 (es) Moduladores de hexahidro-ciclooctilpirazol cannabinoides.
TW200800211A (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
EP2516420B1 (en) Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists